November 16, 2020: We agree that the FDA should immediately develop clear guidelines for labeling that addresses safety and effectiveness of drugs in the geriatric population.
Read More »On Medical Treatments & Products
NCHR Statement at FDA Alzheimer’s Advisory Committee Meeting On Aducanumab
November 6, 2020: Aducanumab could be promising, but we need better evidence before approving it.
Read More »NCHR’s Testimony at FDA Meeting for Reducer Circulatory System Device
October 27, 2020: The data provided thus far simply do not provide enough evidence that there are benefits outweighing the risks for the Reducer, a permanent device.
Read More »NCHR Statement by Dr. Diana Zuckerman at FDA Covid Vaccine Advisory Committee October 22, 2020
October 22, 2020: It is FDA’s job to make sure that a vaccine has meaningful benefits for the health and lives of most Americans, and especially those most at risk.
Read More »NCHR’s Statement at FDA Advisory Committee Meeting on Olanzapine and Samidorphan Combination Tablets
October 9, 2020: Although patients may benefit from olanzapine/samidorphan by experiencing lower weight gain, the risks are too high to justify approval.
Read More »